 | Up a level |
Dibitetto, Diego; Liptay, Martin; Vivalda, Francesca; Dogan, Hülya; Gogola, Ewa; González Fernández, Martín; Duarte, Alexandra; Schmid, Jonas A; Decollogny, Morgane Francine; Francica, Paola; Przetocka, Sara; Durant, Stephen T; Forment, Josep V; Klebic, Ismar; Siffert, Myriam; de Bruijn, Roebi; Kousholt, Arne N; Marti, Nicole A; Dettwiler, Martina; Sørensen, Claus S; ... (2024). H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours. Nature communications, 15(4430) Nature Publishing Group 10.1038/s41467-024-48715-1
Bhin, Jinhyuk; Paes Dias, Mariana; Gogola, Ewa; Rolfs, Frank; Piersma, Sander R; de Bruijn, Roebi; de Ruiter, Julian R; van den Broek, Bram; Duarte, Alexandra A; Sol, Wendy; van der Heijden, Ingrid; Andronikou, Christina; Kaiponen, Taina S; Bakker, Lara; Lieftink, Cor; Morris, Ben; Beijersbergen, Roderick L; van de Ven, Marieke; Jimenez, Connie R; Wessels, Lodewyk F A; ... (2023). Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors. Cell reports, 42(5), p. 112538. Cell Press 10.1016/j.celrep.2023.112538
Zingg, Daniel; Bhin, Jinhyuk; Yemelyanenko, Julia; Kas, Sjors M; Rolfs, Frank; Lutz, Catrin; Lee, Jessica K; Klarenbeek, Sjoerd; Silverman, Ian M; Annunziato, Stefano; Chan, Chang S; Piersma, Sander R; Eijkman, Timo; Badoux, Madelon; Gogola, Ewa; Siteur, Bjørn; Sprengers, Justin; de Klein, Bim; de Goeij-de Haas, Richard R; Riedlinger, Gregory M; ... (2022). Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature, 609(7929), E13. Springer Nature 10.1038/s41586-022-05287-8
Zingg, Daniel; Bhin, Jinhyuk; Yemelyanenko, Julia; Kas, Sjors M; Rolfs, Frank; Lutz, Catrin; Lee, Jessica K; Klarenbeek, Sjoerd; Silverman, Ian M; Annunziato, Stefano; Chan, Chang S; Piersma, Sander R; Eijkman, Timo; Badoux, Madelon; Gogola, Ewa; Siteur, Bjørn; Sprengers, Justin; de Klein, Bim; de Goeij-de Haas, Richard R; Riedlinger, Gregory M; ... (2022). Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature, 608(7923), pp. 609-617. Springer Nature 10.1038/s41586-022-05066-5
Gogola, Ewa; Duarte, Alexandra A; de Ruiter, Julian R; Wiegant, Wouter W; Schmid, Jonas A; de Bruijn, Roebi; James, Dominic I; Guerrero Llobet, Sergi; Vis, Daniel J; Annunziato, Stefano; van den Broek, Bram; Barazas, Marco; Kersbergen, Ariena; van de Ven, Marieke; Tarsounas, Madalena; Ogilvie, Donald J; van Vugt, Marcel; Wessels, Lodewyk F A; Bartkova, Jirina; Gromova, Irina; ... (2018). Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality. Cancer cell, 33(6), 1078-1093.e12. Cell Press 10.1016/j.ccell.2018.05.008
